Stearic Acid

Stearic Acid

SCHEMBL840883

CCCCCCCCCCCCCCCCCC(=O)[O-].C[N+](C)(C)CCO

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Stearic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
FABP3 P05413 7/20 0.55
CA1 P00915 1/20 0.52
BBOX1 O75936 2/20 0.48
CES2 O00748 3/20 0.48
CES1 P23141 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Decanoic Acid SCHEMBL580470 1.00 FABP3 (0.55) FABP3CA1BBOX1CES2CES1
Nonanoate SCHEMBL29370695 1.00 FABP3 (0.55) FABP3CA1BBOX1CES2CES1
Dodecanoate SCHEMBL19253062 1.00 FABP3 (0.55) FABP3CA1BBOX1CES2CES1
Palmitic Acid SCHEMBL10396224 1.00 FABP3 (0.55) FABP3CA1BBOX1CES2CES1
Octanoic Acid SCHEMBL2761867 1.00 FABP3 (0.55) FABP3CA1BBOX1CES2CES1
Myristic Acid SCHEMBL8588822 1.00 FABP3 (0.55) FABP3CA1BBOX1CES2CES1
Stearic Acid SCHEMBL3459529 0.98 FABP3 (0.53) FABP3CA1BBOX1CES2CES1
Myristic Acid SCHEMBL5317287 0.98 FABP3 (0.53) FABP3CA1BBOX1CES2CES1
Dodecanoate SCHEMBL5320074 0.98 FABP3 (0.53) FABP3CA1BBOX1CES2CES1
Decanoic Acid SCHEMBL5318916 0.98 FABP3 (0.53) FABP3CA1BBOX1CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 289 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023174433-A1 SOLID, SEMISOLID, OR LIQUID COMPOSITIONS FOR AUGMENTING THE STABILITY, PERMEABILITY AND BIOAVAILABILITY OF ACTIVE PHARMACEUTICAL SUBSTANCES Smart Pharmaceutical (Suzhou) Co., Ltd. (CN) 2023-09-21 WO claimed
WO-2021231566-A1 THE USE OF CHOLINE SUPPLEMENTATION AS THERAPY FOR APOE4-RELATED DISORDERS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2021-11-18 WO claimed
US-20210353566-A1 THE USE OF CHOLINE SUPPLEMENTATION AS THERAPY FOR APOE4-RELATED DISORDERS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2021-11-18 US claimed
US-10736912-B2 Compositions containing PUFA and/or uridine and methods of use thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2020-08-11 US claimed
CN-105916969-B Removal of free fatty acids from glyceride oils 贝尔法斯特女王大学 2020-03-20 CN claimed
US-20190167705-A1 COMPOSITIONS CONTAINING PUFA AND-OR URIDINE AND METHODS OF USE THEREOF MASSACHUSETTS INSTITUE OF TECHNOLOGY (US) 2019-06-06 US claimed
EP-3074493-B1 REMOVAL OF FREE FATTY ACIDS FROM GLYCERIDE OILS UNIV BELFAST (GB) 2019-01-09 EP claimed
US-10086009-B2 Compositions containing pufa and/or uridine and methods of use thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGIES (US) 2018-10-02 US claimed
US-20180187122-A1 REMOVAL OF FREE FATTY ACIDS FROM GLYCERIDE OILS THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2018-07-05 US claimed
CN-108138080-A Free fatty is removed from glyceride oil 英国贝尔法斯特女王大学 2018-06-08 CN claimed
CN-101415328-A Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same MASSACHUSETTS INST TECHNOLOGY (US) 2009-04-22 CN claimed
EP-1986662-A2 METHODS AND COMPOSITIONS FOR AMELIORATING OR INHIBITING DECLINE IN MEMORY OR INTELLIGENCE OR IMPROVING SAME Massachusetts Institute of Technology (MIT) (US) 2008-11-05 EP claimed
EP-1870103-A2 Use of uridine in combination with choline for the treatment of memory disorders Massachusetts Institute of Technology (US) 2007-12-26 EP claimed
WO-2007089703-A2 METHODS AND COMPOSITIONS FOR AMELIORATING OR INHIBITING DECLINE IN MEMORY OR INTELLIGENCE OR IMPROVING SAME MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2007-08-09 WO claimed
US-20060241077-A1 Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2006-10-26 US claimed
JP-2003517437-A 2003-05-27 JP claimed
US-20020028787-A1 Nervous system disorders; administering exogenous uridine compound NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-03-07 US claimed
EP-1140104-A1 METHODS FOR INCREASING CYTIDINE LEVELS IN VIVO AND TREATING CYTIDINE-DEPENDENT HUMAN DISEASES Massachusetts Institute of Technology (US) 2001-10-10 EP claimed
EP-0331948-B1 PHARMACEUTICAL COMPOSITION FOR THE TRANSDERMAL ADMINISTRATION OF HEPARIN SCHUR PHARMAZEUTIKA GMBH & CO KG (DE) 1992-01-15 EP claimed
EP-0331948-A2 Pharmaceutical composition for the transdermal administration of heparin SCHUR PHARMAZEUTIKA GMBH & CO KG (DE) 1989-09-13 EP claimed